Indaptus Q3 2022: cash $28.5M, loss $0.42/share; Decoy20 Phase 1 to start Q4 2022

Indaptus Therapeutics, Inc.

2023-Q3 EPS reported -$1.29

Cash, equivalents and marketable securities of $28.5M as of Sep 30, 2022, down from $39.1M at Dec 31, 2021.
R&D expenses of $1.6M in Q3 2022, up $900K vs Q3 2021, driven by Phase 1 trial preparation and manufacturing costs.
G&A expenses of $2.0M in Q3 2022, down $700K vs Q3 2021, due to lower merger-related costs.
Loss per share of $0.42 in Q3 2022 vs $0.81 in Q3 2021; net loss of $2.3M for the quarter.
Phase 1 trial of Decoy20 for solid tumors remains on track to initiate in Q4 2022 after FDA IND clearance in May.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Indaptus Therapeutics, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 10, 2022, Indaptus Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s results of operations for the third quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

Indaptus Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-22-031383

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.